Pramod Gupta, PhD, SVP of Pharmaceutical Operations at Spectrum Pharmaceuticals will be speaking on "Research Opportunities in Current Health Care Environment".
Friday, October 26th (Nevada Day)
11:30 check-in, 12 pm Lunch & Talk
McCormick & Schmicks
$30 RSVP here
(UNLV Students & Researchers - free! Please RSVP)
Spectrum Pharmaceuticals (SPPI) is a biotechnology company with a primary focus in oncology and hematology. Its headquarters is in Henderson, Nevada.
Spectrum has three oncology drugs in the market: FUSILEV® (levoleucovorin), FOLOTYN® (pralatrexate injection) and ZEVALIN® (ibritumomab tiuxetan).
Spectrum has an expertise in acquiring differentiated drugs and a growing pipeline of candidates in Phase 2 and Phase 3 trials (10 drugs in the pipeline).
Spectrum Pharmaceuticals is one of the fastest growing companies in biotechnology. It has a massive pipeline, two marketed drugs, and is very cash rich. (Brian Nichols, Sept 2, 2012 Seeking Alpha). Spectrum's revenues are expected to increase by 50% to $300 million in 2012.